Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Plos One|February 4, 2017
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assayJiuping Ji, Yiping Zhang, Christophe E Redon, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)Shivaani Kummar, Geraldine O'Sullivan Coyne, Khanh T Do, et al.
Investigational New Drugs|June 28, 2021
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumorsShivaani Kummar, Apurva K Srivastava, Tony Navas, et al.
Cancers|August 26, 2022
Performances of Functional and Anatomic Imaging Modalities in Succinate Dehydrogenase A-Related Metastatic Pheochromocytoma and ParagangliomaMayank Patel, Abhishek Jha, Alexander Ling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2022
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part SarcomaJames Nguyen, Naoko Takebe, Shivaani Kummar, et al.
Investigational New Drugs|June 18, 2015
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsKhanh Do, Giovanna Speranza, Lun-Ching Chang, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancersJibran Ahmed, Geraldine O'Sullivan Coyne, Larry V Rubinstein, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2023
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumorsArjun Mittra, Geraldine H O' Sullivan Coyne, Jennifer Zlott, et al.
AJR. American Journal of Roentgenology|August 25, 2021
Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using 68Ga-DOTATATE, FDG, 18F-FDOPA, and 18F-FDA)Abhishek Jha, Mayank Patel, Jorge A Carrasquillo, et al.
Pageof 11